Uniqure NV (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Dan Soland as the new Chief Executive Officer of the Company. Mr. Soland will succeed Jörn Aldag, who has decided to step down as CEO, a role he has held since 2009. Mr. Soland will also be nominated for appointment to uniQure’s Management Board, subject to approval by the Company’s General Meeting of Shareholders. Mr. Aldag will be available to assist the Company during the transition.
Mr. Soland, 57, brings to uniQure more than 30 years of industry experience, most recently serving as Vice President and Chief Operating Officer of ViroPharma. At ViroPharma, Mr. Soland was responsible for building the company’s organization and commercial infrastructure until its successful sale to Shire in 2014 for approximately $4 billion. Mr. Soland was previously President of Chiron Vaccines, where he helped engineer a turnaround that contributed to Chiron’s acquisition by Novartis. Earlier, he was President and CEO of Epigenesis Pharmaceuticals and Vice President and Director of Worldwide Marketing Operations at GlaxoSmithKline Biologicals and held positions of increasing responsibility at Pasteur-Merieux’s Connaught Laboratories (now Sanofi Pasteur). Mr. Soland holds a B.S. in Pharmacy from the University of Iowa.
“Dan’s appointment comes at an important time in the evolution and growth of uniQure,” commented Will Lewis, Chairman of uniQure’s Nomination and Governance Committee who led the search on behalf of the Supervisory Board. “He brings significant operational experience and knowledge of drug development that will be critical as uniQure’s pipeline advances into later-stage clinical studies. I am confident that Dan’s track record of generating shareholder value will enable uniQure to achieve the potential that we all believe is inherent in uniQure’s broad pipeline and leading gene therapy technology platform.”
“The Supervisory Board thanks Jörn for the leadership, energy and commitment that he has brought to uniQure since 2009. Without his significant contributions and leadership, uniQure would not have achieved its successes over the past six years,” continued Mr. Lewis.
“uniQure presents an exciting opportunity and I very much look forward to collaborating with the team on both sides of the Atlantic to advance our innovative portfolio of gene therapy candidates to patients,” commented Mr. Soland.(Original Source)
Shares of uniQure are down 5.17% to $16.50 in early morning trading. QURE has a 1-year high of $36.38 and a 1-year low of $13.89. The stock’s 50-day moving average is $18.71 and its 200-day moving average is $24.06.
On the ratings front, uniQure has been the subject of a number of recent research reports. In a report issued on December 1, WallachBeth Capital LLC analyst Bob Ai reiterated a Buy rating on QURE, with a price target of $60, which represents a potential upside of 244.8% from where the stock is currently trading. Separately, on the same day, Chardan’s Gbola Amusa MD CFA reiterated a Buy rating on the stock and has a price target of $40.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Bob Ai and Gbola Amusa MD CFA have a total average return of -10.6% and 1.2% respectively. Ai has a success rate of 30.0% and is ranked #3110 out of 3643 analysts, while CFA has a success rate of 50.6% and is ranked #1525.
Overall, 8 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $45.00 which is 158.6% above where the stock closed yesterday.
uniQure NV is engaged in the field of gene therapy and has developed a gene therapy product to receive regulatory approval in the European Union.